InMode's fractional RF microneedling handpiece engineered for vaginal tissue remodelling. Morpheus8 V delivers controlled submucosal RF energy to stimulate collagen and elastin regeneration, improve tissue tone and lubrication, and address stress urinary incontinence — with no surgical intervention.
Submucosal RF DeliveryFractional microneedling penetrates the vaginal mucosa to stimulate deep collagen remodelling
Morpheus8 V is indicated for the remodelling of vaginal tissue in women seeking non-surgical intimate wellness solutions. Fractional RF energy delivered submucosally stimulates neocollagenesis and neoelastogenesis, improving tissue quality, tone, and function.
Vaginal Laxity
Fractional RF stimulates submucosal collagen remodelling and tissue contraction, addressing loss of vaginal tone commonly associated with childbirth and ageing. Patients typically report improved sensation and tightness following a course of treatments.
Vaginal Dryness & Atrophy
RF-induced tissue remodelling stimulates mucosal regeneration and improved lubrication — particularly relevant for peri- and post-menopausal patients experiencing genitourinary syndrome of menopause (GSM). Reduces symptoms of dryness, irritation, and dyspareunia.
Stress Urinary Incontinence (SUI)
Submucosal collagen stimulation in the anterior vaginal wall can improve urethral support and reduce mild to moderate SUI symptoms. Most effective when combined with EmpowerRF's FormaV or VTone modalities as part of a comprehensive women's wellness protocol.
Post-Partum Tissue Remodelling
Addresses tissue changes following vaginal delivery, including reduced tone and altered sensation. Treatment can typically commence from 3 months post-delivery once tissue has fully healed. Combination protocols with FormaV are commonly used for comprehensive outcomes.
Labia Majora & Introitus
Morpheus8 V can also be applied to the external introitus and labia majora for surface skin laxity and texture improvement. External labial treatment follows similar depth and energy parameters to facial or body skin, with careful attention to tissue sensitivity.
Treatment Parameters
Clinical parameters based on InMode EmpowerRF clinical guidance. Treatment protocols should be tailored to individual patient anatomy, tissue quality, and clinical indication. All internal vaginal treatments must be performed under topical or local anaesthesia.
Treatment Zone
Mode
Depth
Energy Level
Passes
Vaginal Canal — Initial Treatment
Cycle
1 – 2mm
8 – 12
1 – 2
Vaginal Canal — Subsequent Treatments
Cycle
2 – 3mm
10 – 18
1 – 2
Anterior Wall (SUI Protocol)
Cycle
2 – 3mm
10 – 16
1 – 2
Introitus & Perineum
Cycle
1 – 2mm
8 – 14
1
Labia Majora (External)
Cycle
2 – 3mm
10 – 16
1 – 2
Treatment Session Protocol
Apply topical anaesthetic (e.g. EMLA or equivalent) for a minimum of 30–45 minutes prior to treatment. Place the patient in dorsal lithotomy position. Insert the Morpheus8 V handpiece gently and systematically cover the vaginal canal wall with non-overlapping pulses, rotating the handpiece at regular intervals. Work from the apex toward the introitus. Use a single pass per zone per session for first treatments; experienced practitioners may introduce a second pass in subsequent sessions based on patient tolerance and response.
Important Clinical Notes
Do not treat during active infection, menstruation, or within 3 months of vaginal delivery. Ensure the patient has had a recent gynaecological assessment where clinically appropriate. Avoid treatment in patients with active pelvic inflammatory disease, untreated STIs, or known vaginal malignancy. Do not use metal-containing IUDs or pessaries during treatment without manufacturer confirmation of safety. Post-treatment: patients should avoid intercourse, swimming, and tampon use for 5–7 days. Light spotting or discharge is normal for 24–48 hours post-treatment.
Technical Specifications
Core technical parameters for the Morpheus8 V handpiece. Contact your STERN Laser representative for full clinical documentation and operator training requirements.
Topical (minimum 30–45 min); local infiltration for higher energy treatments
Treatment Schedule
3 sessions spaced 4–6 weeks apart; maintenance every 6–12 months
Contraindications
Active vaginal infection, menstruation, pregnancy, metal IUDs (confirm safety), vaginal malignancy, PID
Post-Treatment Restrictions
No intercourse, swimming, or tampon use for 5–7 days post-treatment
Compatible Workstation
EmpowerRF
Complementary Handpieces
FormaV, VTone, Aviva, D-Tone (all EmpowerRF)
FAQs
Common questions about Morpheus8 V treatments. Contact STERN Laser for clinical guidance specific to your practice and patient population.
Morpheus8 V is used to treat vaginal laxity, vaginal dryness and atrophy (including genitourinary syndrome of menopause), mild to moderate stress urinary incontinence, reduced sensation, and post-partum tissue changes. It can also be applied to the external introitus and labia majora for skin laxity and texture improvement. It is not a treatment for gynaecological pathology and patients should have an appropriate gynaecological assessment before proceeding.
Most patients tolerate Morpheus8 V well with topical anaesthetic applied 30–45 minutes before treatment. Patients typically report a mild pressure sensation and warmth during the procedure. For higher energy settings or more sensitive patients, local anaesthetic infiltration or oral pain relief can be used as an adjunct. Treatment time is typically 20–30 minutes once anaesthesia is in place.
A standard course consists of 3 sessions spaced 4–6 weeks apart. Some patients begin noticing improvements in tissue tone and lubrication from 4–6 weeks after the first treatment as collagen remodelling commences. The most notable results typically emerge 3–6 months after completing the full treatment course. Maintenance treatments every 6–12 months are recommended to sustain outcomes.
Morpheus8 V has minimal social downtime. Patients may experience mild discomfort, light spotting, or a small amount of watery discharge for 24–48 hours post-treatment. A restriction on intercourse, tampon use, and swimming for 5–7 days is recommended. Most patients return to normal daily activities the same day. Patients should avoid hot baths and vigorous exercise for 48 hours post-treatment.
Morpheus8 V is contraindicated in patients with active vaginal or pelvic infection, untreated STIs, current menstruation, pregnancy, known vaginal malignancy, or active pelvic inflammatory disease. Patients with metal-containing IUDs should seek manufacturer confirmation before proceeding. Patients who have had vaginal delivery should wait a minimum of 3 months post-partum. Patients on anticoagulant therapy may require cessation 7–10 days prior to treatment, subject to their treating physician's approval.
Yes. Morpheus8 V is most commonly combined with FormaV (radiofrequency tissue warming) and VTone (intravaginal EMS for pelvic floor muscle rehabilitation) as part of a comprehensive women's wellness protocol on the EmpowerRF platform. FormaV is typically performed first to warm the tissue, followed by Morpheus8 V in the same session, with VTone used in alternating sessions or at home via the patient handset. Your STERN Laser clinical trainer will guide you on combination sequencing and timing.
Platform Compatibility
Compatible Workstation
Morpheus8 V is exclusively compatible with the EmpowerRF workstation by InMode — the multi-functional women's wellness platform available through STERN Laser.
